Innogenetics and Bio-Rad enter into a non-exclusive licensing agreement for HIV-2 patents
Innogenetics and Bio-Rad Laboratories, Inc. announced that the two companies have finalized a non-exclusive licensing agreement for patents in the field of viral diagnostics. According to the terms of the non-exclusive agreement, Innogenetics will get a license from Bio-Rad that has exclusive rights in the field of HIV-2. Bio-Rad will get an option to a non-exclusive license under Innogenetics patents in the field of HCV genotyping.
Under the agreement, Innogenetics will be granted a non-exclusive license to Bio-Rad's intellectual property in the field of HIV-2 immunoassays and, consequently, all legal proceedings between Innogenetics, Institut Pasteur, Bio-Rad Pasteur, and Bio-Rad Laboratories b.v. will be terminated. The HIV-2 license granted to Innogenetics covers all territories (except the USA and Canada) and runs until the expiration of the last to expire of the licensed patents.
The proceedings were initiated by the aforementioned parties in 1998 and were related to the Institute Pasteur's European patents EP 239 425 and EP 283 327. Based on these patents, claims were pending against Innogenetics at the Courts of Antwerp and Gent, respectively.
In addition, Bio-Rad will be granted an option to Innogenetics HCV genotyping patents. This option is non-exclusive and covers all territories.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Alagille_syndrome
Sociological_and_cultural_aspects_of_Tourette_syndrome

Millions in funding to revolutionize immunotherapy - Swiss start-up NXI Therapeutics extends pre-seed financing to CHF 3.5 million in run-up to larger seed financing
Portopulmonary_hypertension

A new way to treat HIV identified
Haplogroup_J_(Y-DNA)

A well-known anti-ageing compound with a new target - Researchers discover an unexpected link between DNA winding and metabolism in the gut to ameliorate ageing
Francisella_tularensis
Category:Antiandrogens
Category:Genetics_or_genomics_research_institutions
Elbion AG Completes EUR 25 Million Series A Financing
